138 related articles for article (PubMed ID: 22571922)
1. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Huang PY; Li Y; Mai HQ; Luo RZ; Cai YC; Zhang L
Oral Oncol; 2012 Oct; 48(10):964-968. PubMed ID: 22571922
[TBL] [Abstract][Full Text] [Related]
2. Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Shen C; Chen L; Fu J; Lin H
J Cancer Res Ther; 2016 Oct; 12(Supplement):72-75. PubMed ID: 27721259
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
Wang D; Zhou J; Zheng J; Zhang J; Chen Y; Li W; Wang R
Cancer Biomark; 2018; 21(4):875-881. PubMed ID: 29439312
[TBL] [Abstract][Full Text] [Related]
4. Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?
Chan SH; Cheung FM; Ng WT; Choi CW; Cheung KN; Yiu KH; Lee AW
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1414-20. PubMed ID: 20605357
[TBL] [Abstract][Full Text] [Related]
5. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer.
Lee HW; Hwang YH; Han JH; Choi JH; Kang SY; Jeong SH; Ann MS; Oh YT; Kim JH; Kim CH; Sheen SS
Oral Oncol; 2010 Mar; 46(3):209-13. PubMed ID: 20153243
[TBL] [Abstract][Full Text] [Related]
6. Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy.
Huang PY; Zeng TT; Ban X; Li MQ; Zhang BZ; Zhu YH; Hua WF; Mai HQ; Zhang L; Guan XY; Li Y
BMC Cancer; 2016 Aug; 16(1):669. PubMed ID: 27549330
[TBL] [Abstract][Full Text] [Related]
7. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial.
Peng H; Chen L; Li WF; Guo R; Mao YP; Zhang Y; Guo Y; Sun Y; Ma J
Cancer; 2017 May; 123(9):1643-1652. PubMed ID: 28001301
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
[TBL] [Abstract][Full Text] [Related]
9. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.
Sun JM; Ahn MJ; Park MJ; Lee HY; Ahn JS; Lee S; Kang G; Han J; Son YI; Baek CH; Ahn YC; Park K
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):655-60. PubMed ID: 21621119
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy.
Chen C; Wang F; Wang Z; Li C; Luo H; Liang Y; An X; Shao J; Li Y
Cancer Chemother Pharmacol; 2013 Aug; 72(2):315-22. PubMed ID: 23712330
[TBL] [Abstract][Full Text] [Related]
11. Expression of BRCA1 and ERCC1 as predictive clinical outcome after radiochemotherapy in patients with locoregionally moderate-advanced nasopharyngeal carcinoma.
Xu S; Yu Y; Rong J; Hu D; Zhang L; Fu S; Yang H; Fan J; Yang L; Wu J
Oncotarget; 2017 May; 8(19):31355-31367. PubMed ID: 28404895
[TBL] [Abstract][Full Text] [Related]
12. A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
Wang Y; Wang ZQ; Jiang YX; Wang FH; Luo HY; Liang Y; Wang DS; Li YH
Expert Opin Pharmacother; 2016 Aug; 17(12):1585-90. PubMed ID: 27328125
[TBL] [Abstract][Full Text] [Related]
13. Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy.
Zhang Z; Jiang C; Hu L
Tumori; 2014; 100(3):328-32. PubMed ID: 25076246
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.
Liu T; Li Y; Song J; Li B; Wang R; Huang T; Qin Y
Cancer Control; 2024; 31():10732748241251562. PubMed ID: 38716503
[TBL] [Abstract][Full Text] [Related]
15. [Correlation between expression of ERCC1 and the treatment of cisplatin-based chemotherapy in local advanced nasopharyngeal carcinoma].
Li W; Sun Q; Lu M
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(2):144-6. PubMed ID: 25989663
[TBL] [Abstract][Full Text] [Related]
16. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
Ryu H; Song IC; Choi YS; Yun HJ; Jo DY; Kim JM; Ko YB; Lee HJ
Medicine (Baltimore); 2017 Dec; 96(51):e9402. PubMed ID: 29390553
[TBL] [Abstract][Full Text] [Related]
18. Correlation between ERCC1 expression and concurrent chemotherapy and radiotherapy in patients with locally advanced nasopharyngeal cancer.
Liang R; Lin Y; Liu ZH; Liao XL; Yuan CL; Liao SN; Li YQ
Genet Mol Res; 2015 May; 14(2):5804-11. PubMed ID: 26125779
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of excision repair cross-complementation group 1 protein in locoregionally advanced nasopharyngeal carcinomas receiving cisplatin-based concurrent chemoradiotherapy.
Zhou J; Wang D; Zheng JH; Wang Z; Xie B; Zhang WM
J Cancer Res Ther; 2018; 14(Supplement):S145-S151. PubMed ID: 29578165
[TBL] [Abstract][Full Text] [Related]
20. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]